Resultados de la búsqueda 131-140 of 3582 for charcoal-activated-oral-route

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  2. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  3. Stage 4 (metastatic) colon cancer - Diagnósticos y tratamientos - Mayo Clinic

    Find out about symptoms and complications for this advanced stage of colon cancer. Learn about treatment options, including chemotherapy, ...

  4. Ensayos clínicos - Centro Pediátrico de Mayo Clinic

    The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as ...

  5. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). However ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... orally in subjects with Relapsed/Refractory (r/r) ... The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following ...

  9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma ...